Please see the Children's Health Coalition response to today's announcement. It’s critical to protect children in all settings by ensuring vaccination of adults in their ecosystem – whether that’s in the community, in schools and in healthcare and social service settings.

Report on a #Delta outbreak in elementary #school 80% of kids in front 2 rows infected! - Can we pls take school precautions seriously? - Kids <12 yrs unvaxxed & vulnerable - Don't take off your mask (to read aloud)! - Wear a (good) mask **correctly** 👇 cdc.gov/mmwr/volumes/7…

Nous acceptons maintenant les candidatures pour la Bourse #Loran2022! Nous recherchons des jeunes engagé·e·s pour rejoindre la prochaine classe des Boursier·ère·s Loran. Diffusez ce message aux étudiant·e·s qui postulent à l'université l'automne prochain : boursierloran.ca/devenir-boursi…

Safety & immunogenicity of a booster dose of BNT162b2 given 7 to 9 mos after two-dose series suggest that a third dose could prolong protection and further increase the breadth of protection. #Covid19Vaccines #COVID19 #SARSCoV2 #IDTwitter nej.md/2Z150g3

Congrats to Institute for Protein Design and @DeepMind. As Holden Thorp, dormant account wrote we are in an era of “protein structure for all”. And please check out the great list of runners up. Including, pills against COVID and CRISPR gene-editing inside the body.

Can we correlate #SARSCoV2 spike (S) biochemical properties with the specificity, magnitude & quality of antibody responses? Put another way, how to make a good #CovidVaccine ? @johnbowenbio led the charge to answer these questions HHMI 1/21 biorxiv.org/content/10.110…

75 years of research on human diseases in 1 minute

This is conceptually insane. nature.com/articles/s4146…

Check out this review article from my postdoc Pat Byrne (@antigenman) on structure-based vaccine antigen design! authors.elsevier.com/a/1f63R3OeyGDh…

Brad Nelson epitomized the spirit of this award, telling the real human story of an amazing scientific journey - delivered with humor and humility! Congrats Brad and well deserved.

Important to note that both Moderna and Pfizer/BioNTech Omicron (BA-1) booster shots had 3-fold lower neutralizing antibody response to BA.4/5 than to BA.1 [Pfizer data just put out this morning)

86% efficacy for the Pfizer Inc. RSV prefusion F vaccine in the elderly is extremely good news! Looks like there will be multiple RSV vaccines available soon for this target population. Still looking forward to seeing the data later this year from their maternal vaccine trial.

The SickKids Research Institute is hiring! Seeking outstanding scientist whose research program is focused on biological molecule- or cell-based therapeutics, diagnostics or preventative medicine strategies, their design and their mechanisms of action. nature.com/naturecareers/…

More great news for RSV vaccines (and structure-based vaccine design), this time for maternal immunization! apnews.com/article/scienc…

It's an incredible day for structure-based vaccine design, and I'm thrilled to see our prefusion RSV F antigen get approved as the first RSV vaccine. Still more work to do to reduce the RSV disease burden, but this will help! Congrats Barney Graham, MD, PhD! cnn.com/2023/05/03/hea…

We're recruiting SickKids Foundation!! Faculty position for research at the interface between computational design, structural biology, and therapeutic development: Molecular Engineering by Machine Learning | Apply before 7 Nov 2023 | nature.com/naturecareers/…

Excited to share our latest publication Immunity: "Analysis of the Human B Cell Response to HCMV in Top Neutralizers from a cohort of 9,000 Individuals"! Congrats to Matthias Zehner, Artem Ashurov and Mira and thanks to all collaboration partners! sciencedirect.com/science/articl…

Working with a great team including #KatherineHarris to organize Keystone Symposia #AntibodyDrugs: Innovative Formats, Design and Engineering, February 17-20, 2025! Join us to explore emerging research in Keystone! keysym.us/KSAntibodyDrug… #KSAntibodyDrugs25

Come share your latest antibody research Keystone Symposia Antibodies as Drugs: Innovative Formats, Design and Engineering!! keysym.us/KSAntibodyDrug… 10 days left to submit your abstracts to be considered for short talks and scholarships! Short Talk Abstract Deadline: Nov 13, 2024

Last day to submit your abstract to be considered for a short talk and scholarship #Keystone Symposia on #Antibodies as Drugs: Innovative Formats, Design and Engineering!! lnkd.in/geiJuFYB! Scholarship and Short Talk Abstract Deadline: Nov 13!